JPS61100184A - Health food - Google Patents

Health food

Info

Publication number
JPS61100184A
JPS61100184A JP59220913A JP22091384A JPS61100184A JP S61100184 A JPS61100184 A JP S61100184A JP 59220913 A JP59220913 A JP 59220913A JP 22091384 A JP22091384 A JP 22091384A JP S61100184 A JPS61100184 A JP S61100184A
Authority
JP
Japan
Prior art keywords
vinegar
health food
calcium
acetic acid
acid fermentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59220913A
Other languages
Japanese (ja)
Other versions
JPH07100022B2 (en
Inventor
Junichi Iwamura
淳一 岩村
Hirosuke Sakazaki
坂崎 浩祐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokiwa Kanpo Pharmaceutical Co Ltd
Kinki University
Original Assignee
Tokiwa Kanpo Pharmaceutical Co Ltd
Kinki University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokiwa Kanpo Pharmaceutical Co Ltd, Kinki University filed Critical Tokiwa Kanpo Pharmaceutical Co Ltd
Priority to JP59220913A priority Critical patent/JPH07100022B2/en
Publication of JPS61100184A publication Critical patent/JPS61100184A/en
Publication of JPH07100022B2 publication Critical patent/JPH07100022B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

PURPOSE:To provide a health food effective to decrease the cholesterol level in blood, increase the body weight and suppress the deposition of neutral fat in liver and the deposition of fat to the body, and containing a processed non- volatile salt prepared by neutralizing an unrefined SAKE or vinegar, etc. prepared by acetic acid fermentation with a basic calcium-containing substance, etc. CONSTITUTION:Unrefined SAKE or vinegar prepared by acetic acid fermentation or its separation residue is neutralized with a basic or neutral calcium-containing substance (e.g. calcium hydroxide) to neutralize acidic volatile components to non-volatile components. The treated product is used as a component of the objective health food. The product may be used as it is, or used after the defatting, concentration, drying or pulverization treatment.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 この発明は、酢酸発酵で得たもろみ、食酢または食酢分
離残渣の処理物を有効成分とする、健康食品に関するも
のである。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a health food whose active ingredients are mash obtained by acetic acid fermentation, vinegar, or a processed product of vinegar separation residue.

〔従来の技術〕[Conventional technology]

食酢は、酢酸以外に各種揮発性有機酸、アミノ酸、エス
テル類、糖類を含み、原料に由来する特有の香味および
発酵過程中に生成する芳香、旨味を有するので、調味料
として食生活上重要な位置を占めている。また、これを
飲用すると健康増進に効果があることも知られている。
Vinegar contains various volatile organic acids, amino acids, esters, and sugars in addition to acetic acid, and has a unique flavor derived from the raw materials as well as aromas and umami produced during the fermentation process, making it an important dietary seasoning. occupying a position. It is also known that drinking it is effective for improving health.

しかし、食酢をそのまま飲用することは、その強い酸味
のために容易でなかった。一方、カルシウムは人体に必
要な栄養素の1つであるが、自然界における存在形式は
主として無機塩であって、摂取に好適な形態ではなかっ
た。
However, it has not been easy to drink vinegar as it is due to its strong sour taste. On the other hand, although calcium is one of the nutrients necessary for the human body, its existing form in nature is mainly an inorganic salt, which is not a suitable form for intake.

この発明者は、酢酸発酵で得たもろみ、食酢または食酢
分離残渣の味覚改善および利用方法改善について研究を
霞ねた結果、これらを塩基性ないし中性カルシウム含有
物質で中和すると1食酢およびカルシウムの共存に基づ
く健康増進作用を有し、摂食に適した食品が得られるこ
とを見出し、この発明を完成したのである。
As a result of extensive research into improving the taste and utilization of mash, vinegar, or vinegar separation residue obtained from acetic acid fermentation, the inventor found that by neutralizing these with a basic or neutral calcium-containing substance, 1 vinegar and calcium They discovered that a food product suitable for consumption that has a health-promoting effect based on the coexistence of the following ingredients was completed, and this invention was completed.

〔発明の構成〕[Structure of the invention]

すなわち、この発明は、酢酸発酵で得たもろみ、食酢ま
たはその分離残渣を塩基性ないし中性カルシウム含有物
質で処理することにより、酸性揮発性成分を中和して不
揮発性塩とした処理物を含む。
In other words, the present invention involves treating mash, vinegar, or the separated residue obtained by acetic acid fermentation with a basic or neutral calcium-containing substance to neutralize acidic volatile components and produce a non-volatile salt. include.

健康食品である。It is a health food.

この発明で用いるもろみ、食酢またはその分離残渣は、
酢酸発酵で得られた任意のものであってよい。すなわち
、酒精酢(甘藷、馬鈴藷、精密、パルプ廃液等を原料と
するアルコールから作ったもの)、米酢(米麹から作っ
たもの)、粕酢(清酒粕から作ったもの)、麦芽酢(穀
類を原料とするアルコールから作ったもの)、りんご酢
、ぶどう酢等を得るための公知の酢酸発酵(例えばアセ
トバクチル属のA、オキシダンス、A、アセチゲヌス、
A、キシリヌム、A、アセトスス、A、アセチ、A、ク
エチンギアヌス、A、アセンデンス、A、シュエラエン
バチ等の菌を用い、静置法、速酢法、深部法等の方法に
よる方法)で得られるもろみ1食酢または食酢分離残渣
が用いられる。
The moromi, vinegar or its separated residue used in this invention is
It may be any product obtained by acetic acid fermentation. Namely, alcoholic vinegar (made from alcohol made from sweet potato, potato, precision, pulp waste liquid, etc.), rice vinegar (made from rice malt), lees vinegar (made from sake lees), and malt vinegar (made from rice koji). known acetic acid fermentation to obtain apple cider vinegar, grape vinegar, etc. (made from alcohol made from grain-based alcohol), apple cider vinegar, grape vinegar, etc.
A. xylinum, A. acetosus, A. aceti, A. quetingianus, A. ascendens, A. schellaen bee, etc. Moromi 1 vinegar or vinegar separation residue is used.

また、塩基性ないし中性カルシウム含有物質としては、
水酸化カルシウム、炭酸カルシウム、燐酸カルシウム、
およびこれらを主成分として含有する物質、例えばかき
等の貝から粉末、石灰等が用いられる。塩基性ないし中
性カルシウム含有物質の添加量は、pHを7附近にする
に充分な量が適当である。この処理により、もろみ、食
酢またはその分離残渣中の酢酸、プロピオン酸、酪酸。
In addition, as basic or neutral calcium-containing substances,
Calcium hydroxide, calcium carbonate, calcium phosphate,
and substances containing these as main components, such as powder from shellfish such as oysters, lime, etc. are used. The appropriate amount of the basic or neutral calcium-containing substance added is sufficient to bring the pH to around 7. This treatment removes acetic acid, propionic acid, and butyric acid in mash, vinegar, or its separated residue.

2塩基性酸等が中和される。Dibasic acids etc. are neutralized.

こうして得られた処理物は、これをそのままこハ でもよい。また、粉末を必要に応じて賦形剤と混合し、
錠剤、カプセル、シロップ、顆粒剤、けんだく液等の内
用薬に普通に用いられる剤形に製剤することができる。
The thus obtained treated product may be used as is. Also, the powder can be mixed with excipients if necessary,
It can be formulated into dosage forms commonly used for internal medicine such as tablets, capsules, syrups, granules, and suspensions.

さらに、ヨーグルト、あめ、クツキー、ゼリー等の食品
に混合してもよく、他の医薬、漢方薬、食品粉末、エキ
ス等と混合してもよい。
Furthermore, it may be mixed with foods such as yogurt, candy, kutsky, and jelly, and may be mixed with other medicines, herbal medicines, food powders, extracts, and the like.

〔効果〕〔effect〕

この発明による健康食品は、酢酸発酵で得たもろみ、食
酢またはその分離残渣とカルシウムを含んでいるので、
これらの元来保有する効果およびこれらの共存による効
果により、すぐれた血中コレステロール(特に超低比骸
リポ蛋白および低比1117ボ蛋白)低下作用、体欧増
加、肝中性脂肪沈着、体脂肪沈着抑制作用を有する。
The health food according to this invention contains mash obtained from acetic acid fermentation, vinegar or its separated residue, and calcium.
Due to these inherent effects and the effects of their coexistence, it has an excellent effect on lowering blood cholesterol (especially very low ratio bone lipoprotein and low ratio 1117 protein), increases body weight, liver triglyceride deposition, and body fat. Has a deposition inhibitory effect.

また、揮発性酸を中和しているので、強い酸味、酸臭が
なく、摂食に都合がよい。そして、中和には、塩基性な
いし中性カルシウム含有物質を用いるので、ナトリウム
のような他の金属イオンが大量に含まれるおそれがない
。したがって、健康食品として極めてすぐれたものであ
る。
In addition, since volatile acids are neutralized, there is no strong sour taste or odor, making it convenient for consumption. Furthermore, since a basic or neutral calcium-containing substance is used for neutralization, there is no risk of large amounts of other metal ions such as sodium being included. Therefore, it is extremely excellent as a health food.

この発明の健康食品は、上記のような方法により、成人
1日当り0.5ないし5りの量で摂取するのが適当であ
る。
The health food of this invention is suitably ingested by an adult in an amount of 0.5 to 5 ml per day by the method described above.

〔実施例〕〔Example〕

次に、この発明を実施例により説明し、試験例によりそ
の効果を明らかにする。
Next, this invention will be explained by examples, and its effects will be clarified by test examples.

実施例1 黒酢もろみ60 K9 (固体・液体混合物)に水20
リットルを加え、ホモミキサー(3440rpm)で激
しく攪拌するとゲル状となる。次に、ホモミキサーで攪
拌しながら、これに水酸化カルシウム(1,451’f
)を加えてpHを7に調整する。これを減圧下に濃縮、
乾燥した後ミキサーで粉砕し、中和物12.5 K9を
得る。この際、スクリュープレスで固体と液体に分け、
固体はそのまま減圧または送風乾燥し、液体を減圧濃縮
し、これらを合わせて粉砕すると能率がよい。こうして
得られた中和物を食品分析法によって分析した結果、水
分2.6%、蛋白質18.3%、脂質44.1%、繊維
19.6%、灰分15.4%であった。
Example 1 Black vinegar mash 60 K9 (solid/liquid mixture) and water 20
liter and stir vigorously with a homomixer (3440 rpm) to form a gel. Next, calcium hydroxide (1,451'f) was added to this while stirring with a homomixer.
) to adjust the pH to 7. Concentrate this under reduced pressure,
After drying, it is pulverized with a mixer to obtain a neutralized product 12.5 K9. At this time, separate the solid and liquid using a screw press,
It is efficient to dry the solid as it is under reduced pressure or by blowing air, concentrate the liquid under reduced pressure, and grind them together. As a result of analysis of the thus obtained neutralized product using a food analysis method, the content was 2.6% moisture, 18.3% protein, 44.1% lipid, 19.6% fiber, and 15.4% ash.

実施例2 実施例1で得た健康食品      150 部乳糖 
               90 部上記成分を混
合しゼラチン硬カプセルに充填する。
Example 2 Health food obtained in Example 1 150 parts lactose
90 parts The above ingredients are mixed and filled into hard gelatin capsules.

実施例3 実施例1で得た健康食品       80 部小麦粉
               100  部ショート
ニング           15 部砂糖     
           13 部練乳        
         6 部三温糖          
     18 部炭酸水素ナトリウム       
    0.6部バター             1
0 部水                     
   6 部上記を混合し、焼いてビスケットとする。
Example 3 Health food obtained in Example 1 80 parts Wheat flour 100 parts Shortening 15 parts Sugar
13 parts condensed milk
6 parts Sanwarm sugar
18 parts sodium bicarbonate
0.6 parts butter 1
0 parts water
6 parts Mix the above ingredients and bake to make biscuits.

試験例1(肥満マウスに対する効果) (方法) 体重35gのICR系雄性マウスを24℃、
湿度65%の人工照明(午前7時より午後7時)空調室
で数日間飼育観察のうえ、体重に7あたり0.6gのゴ
ールド(Gold)チオグルコース(シグマ・ケミカル
社)を腹腔内に注射した。
Test Example 1 (Effect on obese mice) (Method) ICR male mice weighing 35 g were incubated at 24°C.
The animals were kept in an air-conditioned room with 65% humidity and artificial lighting (from 7 a.m. to 7 p.m.) for several days, and then intraperitoneally injected with 0.6 g of Gold thioglucose (Sigma Chemical Co.) per 7 days of body weight. did.

注射後2週間の観察期間中一定の体重増加を示さない動
物を除外し、4群に分けて以下の組成の固型飼料で飼育
した。
Animals that did not show a constant weight gain during the observation period of 2 weeks after injection were excluded, and the animals were divided into 4 groups and fed solid feed with the following composition.

1、標準固型飼料(日本フレアー、CE−2)・・・・
・・対照素群 2、上記飼料に3%黒酢モロミ中和物を添加した固型飼
料・・・・・・CT−モロミ中和物群3、上記飼料に3
%黒酢モロミを添加した固型飼料・・・・・・CT−モ
ロミ群 4、上記飼料に3%黒酢エキ文を添加した固型飼料・・
・・・・CT−エスキ群 無処置対照マウスには日本フレアー、CE−2の標準飼
料を投与した。
1. Standard solid feed (Nippon Flare, CE-2)...
... Control group 2, solid feed with 3% black vinegar moromi neutralized product added to the above feed ... CT-Moromi neutralized product group 3, 3% black vinegar moromi neutralized product added to the above feed
Solid feed with % black vinegar moromi added...CT-Moromi group 4, solid feed with 3% black vinegar extract added to the above feed...
...Nippon Flare, CE-2 standard feed was administered to untreated control mice in the CT-Eski group.

体重の増加と飼料の消費量を測定し、6週間上記飼料で
飼育後、マウスは断頭採血し、腸管等の内臓、頭部を除
いた体部の脂肪および肝脂質の定量を行った。
Body weight increase and feed consumption were measured, and after being raised on the above diet for 6 weeks, the mice were decapitated and blood was collected, and internal organs such as the intestines, fat and liver lipids in the body excluding the head were quantified.

血清のブドウ糖、総コレステロール、トリグリセライド
、燐脂質、遊離脂肪酸は酵素法で測定し。
Serum glucose, total cholesterol, triglycerides, phospholipids, and free fatty acids were measured using enzymatic methods.

血清高比屯リポ蛋白(HDL)コレステロールは燐タン
グステン酸、−塩化マグネシウムで超低北東及び低比改
リポ蛋白(VLDL、LDL)を沈殿除去した後、上清
画分中のコレステロールを酵素法で定量した。1) 肝は1gをクロロフォルム・メタノール(2:1゜V/
V)でホモジナイズし、Folch法2)により洗  
1浄して窒素気流中で乾固した。乾固後縁脂質を秤量し
、一定量のクロロフォルム・メタノールに再溶解して、
その1750を用い酵素法によりコレステロール、トリ
グリセライドを測定した。燐脂質はホルフルマイヤー・
フリートの方法3)に従って灰化し、モリブデン/ルー
法により定量した。
Serum high-density lipoprotein (HDL) cholesterol was obtained by precipitating and removing very low NE and low-density lipoproteins (VLDL, LDL) with phosphotungstic acid and magnesium chloride, and then removing cholesterol in the supernatant fraction by an enzymatic method. Quantitated. 1) For liver, add 1 g to chloroform/methanol (2:1°V/
Homogenize with V) and wash using Folch method 2).
1 and dried in a nitrogen stream. Weigh the dried edge lipids, redissolve them in a certain amount of chloroform/methanol, and
Cholesterol and triglyceride were measured using the 1750 using an enzymatic method. Phospholipids are Horflmeier
It was incinerated according to Fleet's method 3) and quantified by the molybdenum/leu method.

体脂肪はクロロフォルム・メタノールでホモジナイズし
て抽出し、その一部をFolch法2)で洗浄後乾固し
、秤量によって値をえた。
Body fat was extracted by homogenizing with chloroform/methanol, a portion of which was washed and dried using the Folch method 2), and the value was obtained by weighing.

(結論) 黒酢製品をゴールドチオグルコースによる肥
満マウス5週間投与し、体重、血清、肝脂質および体脂
肪に対する効果を検討した。黒酢モロミ投与はこれに対
し効果は弱かったが、黒酢モロミ中和物の投与は体重の
増加、血中コレステロール、とくに超低北欧、低比重リ
ポ蛋白コレステロールの上昇、肝中性脂肪や体脂肪の沈
着を抑制しえた。
(Conclusion) Black vinegar products were administered to obese mice induced by gold thioglucose for 5 weeks, and the effects on body weight, serum, liver lipids, and body fat were examined. In contrast, administration of black vinegar moromi had a weak effect, but administration of black vinegar moromi neutralized product increased body weight, increased blood cholesterol, especially ultra-low Nordic cholesterol, increased low-density lipoprotein cholesterol, liver neutral fat, and body fat. It was possible to suppress fat deposition.

(文献) 1、  Burnstein、M、et al 、 :
J、 Lipid Res。
(Reference) 1. Burnstein, M. et al.:
J, Lipid Res.

、11 : 583(1970)・“□2、  Fol
ch、J、 et al、:J、Biol、Chem、
, 11: 583 (1970)・“□2, Fol
ch, J, et al.: J, Biol, Chem.
.

226.497(1957) 3、  Hoeflmyar、J、&Fr1ed、R,
:Med、Ernaehr。
226.497 (1957) 3, Hoeflmyar, J., & Fr1ed, R.
:Med, Ernaehr.

7、1(1966) 試験例2(急性毒性) (1)検体 実施例1の製品 (2)  外観 茶褐色粉末 (3)投与経路 経口 (4)  試験動物 マウス、 ddY−N系雄及び雌 週齢及び開始時体重:約5週齢 雄24〜26y、雌20〜22y (5)室温 22±2℃ (6)試験期間 昭和58年9月15日〜9月22日 (7)検液の調製方法 検体10yに蒸留水を加えて100meとし、液体用高
速ホモゲナイザーで15分間ホモゲナイズしたのち供用
した。
7, 1 (1966) Test Example 2 (Acute Toxicity) (1) Product of Sample Example 1 (2) Appearance: Brown powder (3) Route of administration: Oral (4) Test animal: Mice, ddY-N male and female Age in weeks and starting weight: approximately 5 weeks old, male 24-26y, female 20-22y (5) Room temperature 22±2°C (6) Test period September 15th to September 22nd, 1980 (7) Preparation of test solution Method: Distilled water was added to sample 10y to make 100me, and the sample was homogenized for 15 minutes using a high-speed liquid homogenizer before use.

(8)検波の投与方法等 (1)投与方法 胃ゾンデにより1回、強制経口投与。(8) Detection administration method, etc. (1) Administration method: Forced oral administration once using a gastric tube.

(2) LD5o値の計算方法  プロビット法(3)
検体の投与濃度比  1:1.2(4)1試験群当たり
の動物数  雄、雌各10匹(9)試験結果 (1■ 中毒症状 雄、雌ともにいずれの投与群においても投与直後より何
ら異常はみられず、その後の発育もほぼ正常と思われた
(2) Calculation method of LD5o value Probit method (3)
Administered concentration ratio of specimen: 1:1.2 (4) Number of animals per test group: 10 males and 10 females each (9) Test results (1) Symptoms of toxicity Immediately after administration, both males and females showed no signs of toxicity. No abnormalities were observed, and subsequent growth appeared to be almost normal.

(11)剖検所見 主要臓器に異常は認められなかった。(11) Autopsy findings No abnormalities were observed in major organs.

(121考察 本試験において検体を6,000号勺  まで投与して
も雄、雌ともに死亡例を認めなかった。これは、検波と
して60m1!/に9投与したものであり、マウスに対
する一回強制経口投与量としては最高量と考えられる。
(121 Discussion In this test, no deaths were observed in either males or females even after administering up to 6,000 samples. This was because 9 doses were administered in 60 mL/cm as a detection signal, and the mice were forced once. This is considered the highest oral dose.

又、検波は泥状羊となりこれ以上の濃度では胃ゾンデに
よる投与が不可能であった。したがって、検体の経口L
D5゜値は雄、雌ともに6,0001nf/Kg以上と
した。
In addition, the detection results were muddy, making it impossible to administer with a stomach tube at higher concentrations. Therefore, the oral L of the specimen
The D5° value was set at 6,0001 nf/Kg or higher for both males and females.

特許出願人 岩 村 淳 −はか2名 代 理 人 弁理士 青白 葆 はか1名手続補正書動
式) 1、事件の表示 昭和59年特許願第 220913    号2、発明
の名称 健康食品 3、補正をする者 事件との関係 特許出願人 住所 大阪府相原市大字高井田621−1氏名 台材 
淳 −。よヵ、2名。
Patent applicant Atsushi Iwamura - 2 patent attorneys (1 patent attorney) 1. Indication of the case Patent Application No. 220913 filed in 1982 2. Name of the invention Health food 3. Relationship with the case of the person making the amendment Patent applicant address 621-1 Oaza Takaida, Aihara City, Osaka Prefecture Name Materials
Jun -. Okay, two people.

4、代理人 5、補正命令の日付:昭和60年2月26日(発送日)
7 補正の内容 (1)明細書第3貞第9−13行に、「アセトバクチル
属・・・ノユエツエンバチ」とあるを、次乃通り訂正す
る。
4. Agent 5. Date of amendment order: February 26, 1985 (shipping date)
7 Contents of the amendment (1) In lines 9-13 of the third edition of the specification, the statement "Acetobactyl genus...Noyuetsuenbee" is corrected as follows.

「アセトバクチル(A cetobacter)属のア
セトバクチル・オキンダンス(Acetobacter
 oxydans)、アセトバクチル・アセチゲヌス(
Acetobacter ace−figenus)、
アセトバクチル・キンリヌム(Aceto−bactc
r xylinum)、アセトバクチル・アセトスス(
Acetobacter ace[osus)、アセト
バクチル・アセチ(Acetobacter acet
i)、アセトバクチル・クエチノギアヌス(AccLo
bacLer kuetzingiar+as)、アセ
トバクチル・アセンデンス(A cetobacter
asccndens)、アセトバクチル・ンユエツェン
バヂ(Acetobacter 5chuctzenb
achii)j(2)同第8頁第15行および第9頁第
3行に、rFolchJとあるを、 「ホルタ(Folch)J に訂正する。
"Acetobacter oquindans of the genus Acetobacter"
oxydans), Acetobactyl acetigenus (
Acetobacter ace-figenus),
Acetobactyl quinlinum (Aceto-bactc)
r xylinum), Acetobactyl acetosus (
Acetobacter ace [osus], Acetobacter acet
i), Acetobactyl quetinogianus (AccLo
bacLer kuetzingia+as), Acetobacter ascendens (Acetobacter ascendens)
asccndens), Acetobacter 5chuctzenb
achiii)j (2) On page 8, line 15 and page 9, line 3, the words rFolchJ are corrected to ``Holta (Folch) J.''

(3)同第13頁第+o−+4iテに、rl、Burn
5tein・・・Ernaehr、 Jとあるを、次の
通り訂正する。
(3) rl, Burn on page 13, +o-+4i
5tein...Ernaehr, J is corrected as follows.

Claims (2)

【特許請求の範囲】[Claims] (1)酢酸発酵で得たもろみ、食酢またはその分離残渣
を塩基性ないし中性カルシウム含有物質で処理すること
により、酸性揮発性成分を中和して不揮発性塩とした処
理物を含む、健康食品。
(1) Healthy products containing processed products that neutralize acidic volatile components and turn them into nonvolatile salts by treating mash, vinegar, or their separated residues obtained from acetic acid fermentation with basic or neutral calcium-containing substances. food.
(2)処理物が、そのままのもの、または脱脂、濃縮、
乾燥もしくは粉末化したものである、特許請求の範囲第
1項記載の健康食品。
(2) The processed product is as it is, or is degreased, concentrated,
The health food according to claim 1, which is dried or powdered.
JP59220913A 1984-10-19 1984-10-19 healthy food Expired - Lifetime JPH07100022B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59220913A JPH07100022B2 (en) 1984-10-19 1984-10-19 healthy food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59220913A JPH07100022B2 (en) 1984-10-19 1984-10-19 healthy food

Publications (2)

Publication Number Publication Date
JPS61100184A true JPS61100184A (en) 1986-05-19
JPH07100022B2 JPH07100022B2 (en) 1995-11-01

Family

ID=16758496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59220913A Expired - Lifetime JPH07100022B2 (en) 1984-10-19 1984-10-19 healthy food

Country Status (1)

Country Link
JP (1) JPH07100022B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755610A1 (en) * 1996-11-14 1998-05-15 Dukan Pierre Preparation of dry extract from vinegar that has been enriched with sludge from filtration of crude vinegar
JP2003250497A (en) * 2002-03-05 2003-09-09 Rasheru Seiyaku Kk Health-assisting food
JP2010075076A (en) * 2008-09-25 2010-04-08 Chomei Herushinsu Jozo:Kk Confectionary containing black vinegar and method for preparing confectionary containing black vinegar
KR20150005906A (en) 2012-05-09 2015-01-15 라이온 가부시키가이샤 Food or drink

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5114586A (en) * 1974-07-25 1976-02-05 Daifuku Machinery Works SHIIKEN SUSEIGYO SOCHI

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5114586A (en) * 1974-07-25 1976-02-05 Daifuku Machinery Works SHIIKEN SUSEIGYO SOCHI

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755610A1 (en) * 1996-11-14 1998-05-15 Dukan Pierre Preparation of dry extract from vinegar that has been enriched with sludge from filtration of crude vinegar
JP2003250497A (en) * 2002-03-05 2003-09-09 Rasheru Seiyaku Kk Health-assisting food
JP2010075076A (en) * 2008-09-25 2010-04-08 Chomei Herushinsu Jozo:Kk Confectionary containing black vinegar and method for preparing confectionary containing black vinegar
KR20150005906A (en) 2012-05-09 2015-01-15 라이온 가부시키가이샤 Food or drink

Also Published As

Publication number Publication date
JPH07100022B2 (en) 1995-11-01

Similar Documents

Publication Publication Date Title
US5211956A (en) Pharmaceutical compositions containing phytic acid or its salts
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
WO2014098193A1 (en) Pet food
TWI389697B (en) Improve the composition of lipid metabolism
US8722614B2 (en) Adiponectin production enhancer
FR2527446A1 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF PAPAINE AND CITRIC ACID, WHICH CAN BE TAKEN IN A FOOD OR BEVERAGE
JP2004091464A (en) Obesity inhibitor
JPS61100184A (en) Health food
JP5281895B2 (en) Calcium absorption promoter
CN1768071A (en) Lipid-regulating agent and use thereof
KR101046787B1 (en) Hangover drink composition
KR100828068B1 (en) Composition for preventing or treating hyperlipemia comprising fucoxanthin or marine plant extract containing same
JP3408739B2 (en) Calcium absorption promoter and calcium supplement
JP2002153238A (en) Food, feed and pharmaceutical composition
KR20200120549A (en) Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale
JP2003286180A (en) Obesity inhibitor and food containing the same
KR100832520B1 (en) A composition for the treatment or prevention of osteoporosis comprising an extract of capsosiphon fulvecense
JPH10146166A (en) Physiologically active composition
KR20000060498A (en) Rice including mulberry leaves
JPH0912466A (en) Lipid absorption-inhibiting and extrusion-stimulating agent and high fat food
JP2002114696A (en) Herb drug composed of panax ginseng, panax quinquefolium, panax notiginseng, or the like, its extract, food, quasi-drug and pharmaceutical
KR102490355B1 (en) Composition for preventing, improving or treating obesity comprising bile extract with increased taurochenodeoxycholic acid as an active ingredient and method for preparing the same
JP4338233B2 (en) Appetite food and drink
JP2001002577A (en) Lipid metabolism improver
JP2002255839A (en) Antiobestic drug